Physician profile
Roberta S Hunter
NPI 1801899125
$755.90
in general payments reported to CMS, 2019-2025
11 companies · $17.52 in 2025
The $17.52 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $209 · 2021: $36.31 · 2023: $33.45 · 2024: $25.84 · 2025: $17.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $76.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $76.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $240.40 | 2019-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $141.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.45 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $54.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $53.71 | 2019-2023 | |
| Lilly USA, LLC | $53.32 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $43.73 | 2019-2020 | |
| Pfizer INC. | $36.09 | 2019-2021 | |
| Horizon Therapeutics Plc | $23.75 | 2020 | |
| Abbott Laboratories | $17.52 | 2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.